ARO-HSD

Uses your system voice; voice and rate in settings.

Snapshot

≈ 1 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

ARO-HSD, also known as GSK4532990, is a small interfering RNA developed for the treatment of fatty liver disease. Based on the observation that "loss-of-function HSD17β13 mutations protect against the development of chronic liver disease," the therapeutic attempts to induce this loss of function and thus improve liver disease. The therapy is developed by a partnership of GlaxoSmithKline and Arrowhead Pharmaceuticals that might be worth more than $1 billion.

ARO-HSD, also known as GSK4532990, is a small interfering RNA developed for the treatment of fatty liver disease. Based on the observation that "loss-of-function HSD17β13 mutations protect against the development of chronic liver disease," the therapeutic attempts to induce this loss of function and thus improve liver disease. The therapy is developed by a partnership of GlaxoSmithKline and Arrowhead Pharmaceuticals that might be worth more than $1 billion.

References

Text derived from https://en.wikipedia.org/w/index.php?oldid=1321467265 under CC BY-SA 4.0; modifications have been made.

Provenance

snapshot enwiki-001321467265 · captured 1762796486.0 · version history

Cite this page as: encyclopegia.org, “ARO-HSD”, snapshot enwiki-001321467265. https://encyclopegia.org/a/aro-hsd

Sources cited in this revision

Extracted from the cited revision's reference blocks; absent citations are not invented.